Could Survive Wildfires: SUNY Canton students revolutionize concrete
SUNY Canton Athletes of the Week Feb. 17
According to Canino School of Engineering Technology Associate Professor Saeid Haji Ghasemali, their formulas can provide reduced fire risk, increased durability, lower maintenance and insurance costs.
'Using glass fiber reinforced polymer (GRFP) with lightweight concrete instead of wood could make homes much more fire-resistant and durable, as affected areas look to rebuild,' Haji Ghasemali said. 'While no material is completely fireproof, this combination doesn't burn like wood and can better withstand high temperatures, helping homes survive longer in a wildfire. Plus, it's stronger and doesn't rust, making it a smart choice for building safer, more resilient communities.'
The students replace steel rebar with fiberglass rods to reinforce concrete. Steel rebar can conduct electricity and corrode. The team has found that by using fiberglass rods instead they can improve strength-to-weight ratio, seismic performance and overall sustainability.
'In wildfire-prone areas like California, investing in fire-resistant construction could prevent costly losses and improve safety,' said Haji Ghasemali.
Research by SUNY Canton's students is ongoing in preparation for when the industry adopts it. the American Concrete Institute (ACI) code currently does not include provisions for using Glass Fiber Reinforced Polymer (GFRP) in lightweight concrete. Tests and experiments by SUNY Canton students will help generate the necessary data to fill the gap in the building code, according to the associate professor.
The students' research in the field was selected as one of eight winners of the Spring 2025 Undergraduate Research Session at the annual ACI Convention, to be held on March 31 in Toronto. In 2023, the team came in second place for their research during an ACI competition
'The SUNY Canton ACI Student Chapter highlights the incredible potential and capability of our students and faculty within the Canino School of Engineering Technology,' said Dean Michael J. Newtown. 'Our students have demonstrated their ability to conduct cutting-edge research on the latest technologies in Civil Engineering with real-world applications.'
For more information on SUNY Canton, you can visit their website.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
09-06-2025
- Yahoo
Cardio Diagnostics Holdings, Inc. (CDIO): A Bull Case Theory
We came across a bullish thesis on Cardio Diagnostics Holdings, Inc.(CDIO) on Stock Pursuit's Substack. In this article, we will summarize the bulls' thesis on CDIO. Cardio Diagnostics Holdings, Inc. (CDIO)'s share was trading at $4.4 as of 3rd June according to Yahoo Finance. A biopharmaceutical research laboratory filled with scientists, illuminated by the glow of their equipment. Cardio Diagnostics (CDIO), currently trading below net cash with no long-term debt and $8.7 million in cash against a market cap of just $6.9 million, emerged as a compelling deep value opportunity. While unprofitable, the company is not a typical pharma play—it operates in the epigenetic cardiovascular diagnostics space with clinically approved and already-commercialized tests. Its standout technology uses an AI-driven Integrated Genetic-Epigenetic Engine™ to assess risk for coronary heart disease and other conditions. The flagship tests—Epi+Gen CHD and PrecisionCHD—demonstrate superior sensitivity compared to traditional tools and are the only ones of their kind globally. These tests, along with platforms like ACI and HeartRisk™, position Cardio Diagnostics in rapidly growing markets: the $8.5B coronary risk assessment space, the $24B cardiac biomarker market (9.4–14.1% CAGR), and the epigenetic diagnostics segment (15.5–19% CAGR). While recent quarterly revenue dropped sharply, full-year 2024 revenue doubled, and losses narrowed, aided by lower R&D spend and increased investment in sales personnel. Recent partnerships with medical practices suggest this pivot toward sales execution is already in motion. Though institutional interest is limited, and analyst coverage unclear, the company's sub-net cash valuation, proven IP, and strategic positioning in preventative care make it a logical acquisition target—especially given precedent M&A activity in related diagnostics and genomics spaces. With a potential year of cash runway and peer-reviewed cost-savings data supporting commercial use, Cardio Diagnostics may offer asymmetric upside either through organic traction or a strategic buyout. For value-focused investors, it presents a low-risk, optionality-rich setup worth a small, speculative position. We have covered a standout stock report of a on Fulcrum Therapeutics, Inc. (FULC) by the same author in May 2025. The article summarizes the bulls' thesis on FULC on Stock Pursuit's Substack. Fulcrum Therapeutics (FULC) recently surged over 110% from around $3.30 to $7.00, reflecting growing optimism but also presenting a prime opportunity to take profits. Cardio Diagnostics Holdings, Inc. (CDIO) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 2 hedge fund portfolios held CDIO at the end of the first quarter which was 4 in the previous quarter. While we acknowledge the risk and potential of CDIO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Associated Press
02-04-2025
- Associated Press
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold higher than placebo after 4 immunizations Repeated immunizations amplify the anti-a-syn antibody response, supporting boostability and the potential to further increase antibody titers ACI-7104.056 is well tolerated with no safety issues reported to date Lausanne, Switzerland, April 2, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced additional interim safety and positive immunogenicity data from the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate, for the treatment of patients with early Parkinson's disease (PD). Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: 'We continue to be encouraged by the data emerging from the Phase 2 VacSYn trial of ACI-7104.056 active immunotherapy in early Parkinson's disease. These additional interim safety and immunogenicity data after 6 months of treatment underscore the good safety profile and reinforce the best-in-class characteristics of ACI-7104.056 for the treatment of Parkinson's disease. We look forward to sharing further updates later in 2025.' VacSYn is an adaptive, placebo-controlled, and biomarker-based Phase 2 study in patients with early PD, consisting of two parts with a seamless transition. Part 1 includes initial analyses from over 30 patients randomized to receive ACI-7104.056 or placebo at a ratio of 3:1. To date, in the blinded, pooled active and placebo groups, no serious adverse event considered related to the study drug has been reported. The most common adverse events are mild and transient injection site reactions and headaches, generally of mild severity. Interim results show positive antibody responses were effectively induced against the target antigen at week 6 after 2 immunizations and were further boosted by each additional immunization. Treatment with ACI-7104.056 induced an increase in anti-a-syn antibodies on average over 20-fold higher than the placebo background level after four immunizations. Based on further interim results to be reported later in 2025 including pharmacodynamic and biomarker data, AC Immune may decide to initiate Part 2 of VacSYn with up to 150 patients. Further exploratory endpoints for patients in Part 2 will include the evaluation of the progression of motor and non-motor symptoms of the disease, as well as digital, imaging, and fluid biomarkers. The aim is to establish early proof-of-concept and identification of disease-specific biomarkers for rapid transition into a pivotal study. About ACI-7104.056 ACI-7104.056 is an optimized formulation of its clinically validated anti-a-syn predecessor active immunotherapy which generated a target-specific antibody response against pathological oligomeric a-syn to inhibit spreading and downstream neurodegeneration in early Parkinson's disease. The accumulation of alpha-synuclein protein aggregates has been shown to cause inflammatory stress in cells and contribute to the degeneration of neurons in the brain. It has been known to play a key role in the development of neurodegenerative diseases such as Parkinson's Disease. Previous clinical studies showed the predecessor candidate produced a strong and boostable antibody response with evidence of target engagement and a signal of clinical efficacy. About AC Immune SA AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and NeuroOrphan indications driven by misfolded proteins. The Company's two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties. SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU. The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release. For further information, please contact: Forward looking statements This press release contains statements that constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as 'may,' 'might,' 'will,' 'should,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'predicts,' 'projects,' 'potential,' 'outlook' or 'continue,' and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions 'Item 3. Key Information – Risk Factors' and 'Item 5. Operating and Financial Review and Prospects' in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
Associated Press
26-03-2025
- Associated Press
Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced its participation in the American College of Cardiology's 74th Annual Scientific Session & Expo (ACC.25), taking place March 29-31, 2025, at McCormick Place in Chicago, IL. Cardio Diagnostics will be exhibiting at Booth #2033, showcasing its growing portfolio of advanced cardiovascular solutions, focusing on the Company's PrecisionCHD™ test and its enhanced Actionable Clinical Intelligence (ACI™) report designed to transform how coronary heart disease (CHD) is diagnosed and managed. Cardio Diagnostics' mission is to redefine cardiovascular care by combining epigenetics, genetics, and artificial intelligence to enable earlier detection of heart disease and more personalized patient management. Through our commitment to data-driven innovation, Cardio Diagnostics aims to prevent heart disease, improve diagnostic accuracy, and enable clinicians with actionable insights to deliver targeted, effective care. Spotlight on PrecisionCHD™ and Actionable Clinical Intelligence (ACI™) PrecisionCHD™, Cardio Diagnostics' flagship solution, is a clinical blood test available by prescription to aid in the diagnosis and management of coronary heart disease (CHD). Unlike traditional diagnostic tools, PrecisionCHD™ is radiation-free, requires no fasting, and is performed through a simple blood draw, either via standard phlebotomy or lancet-based sampling. By evaluating a unique panel of 10 genetic and 6 epigenetic (DNA methylation) markers, PrecisionCHD™ provides clinicians with deep insights into the unique underlying molecular drivers of CHD for each patient. Importantly, the test results map epigenetic biomarkers to modifiable risk factors, allowing clinicians to personalize patient management. For cardiologists, PrecisionCHD™ serves as a critical tool in the fight against CHD, offering a non-invasive, radiation-free method to assess molecular drivers of CHD that traditional diagnostics may overlook. With the ability to track changes over time, PrecisionCHD™ empowers cardiologists to refine treatment plans based on a patient's unique epigenetic profile, ultimately driving more effective interventions and better long-term cardiovascular outcomes. This year at ACC.25, Cardio Diagnostics will specifically highlight the updated Actionable Clinical Intelligence (ACI™) report for PrecisionCHD™, now enhanced to provide clearer, easier-to-interpret and more actionable clinical insights. The updated ACI™ leverages PrecisionCHD™'s six key methylation markers, giving prescribing clinicians sharper visibility into their patients' modifiable drivers of disease, including inflammation-related risk - a critical advancement for personalized care. 'PrecisionCHD™ and our enhanced Actionable Clinical Intelligence™ deliver a level of insight that no other solution offers cardiologists today,' said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. 'By integrating epigenetics, genetics, and AI, we provide a clearer, more actionable understanding of a patient's modifiable drivers of coronary heart disease. This empowers cardiologists to deliver truly personalized care and improve patient outcomes.' Poster Presentation - Methylation Biomarkers as Predictors of Mortality in ACS Patients: A Critical Advancement for Clinical Cardiology At ACC.25, Cardio Diagnostics will present compelling new data on the power of the methylation biomarkers of the PrecisionCHD™ test to predict mortality in patients with Acute Coronary Syndrome (ACS), offering cardiologists a novel, actionable tool to guide patient management to help improve survival outcomes. The poster, titled 'Synergistic Effects of Combining Methylation Data with Imaging Data in Predicting Mortality of Acute Coronary Syndrome (ACS) Patients,' highlights findings from a recent study by Cardio Diagnostics demonstrating the superiority of PrecisionCHD methylation indices to angiographic methods for predicting mortality risk in ACS patients. In addition, the study delineates a machine learning-based method that could be integrated within existing electronic health records systems to synergistically combine angiographic and methylation information for predicting mortality risk. By interrogating key methylation pathways linked to inflammation and coronary heart disease, PrecisionCHD™ can enable clinicians to more effectively stratify mortality risk and personalize treatment plans for ACS patients, potentially improving outcomes. 'These findings underscore the power of methylation-based biomarkers in cardiovascular medicine,' said Rob Philibert, M.D., Ph.D., Chief Medical Officer of Cardio Diagnostics. 'Traditional imaging tools provide valuable anatomical insights, but they fall short in predicting long-term mortality risk and providing mechanistic insights. Our study shows that methylation biomarkers not only fill this gap but also offer a more precise, biologically driven assessment of mortality risk, allowing cardiologists to intervene earlier and more effectively.' Visit Cardio Diagnostics at Booth #2033 Attendees are invited to visit Booth #2033 to learn more about the Company's PrecisionCHD™, Epi+Gen CHD™ and Actionable Clinical Intelligence™ solutions, and its broader vision for AI-driven, epigenetic-guided precision cardiovascular medicine. The Company's executive team will also be onsite to engage with cardiologists, potential partners and attendees on how these innovations are transforming cardiovascular care. About Cardio Diagnostics Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine ('Core Technology') for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit Forward-Looking Statements Certain statements and information included in this press release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases 'will', 'will likely result,' 'expected to,' 'will continue,' 'anticipated,' 'estimate,' 'projected,' 'intend,' 'goal,' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended in December 31, 2024, under the heading 'Risk Factors' in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. Investor Relations 855-226-9991 [email protected] & Public Relations Public Relations 855-226-9991 SOURCE: Cardio Diagnostics Holdings, Inc. Copyright Business Wire 2025. PUB: 03/26/2025 08:31 AM/DISC: 03/26/2025 08:32 AM
